Is NCT07550088 recruiting in La Jolla, CA?

Yes, NCT07550088 is currently recruiting participants at its La Jolla, CA location. This colorectal cancer metastatic clinical trial is actively enrolling qualified participants.

How do I join the colorectal cancer metastatic clinical trial in La Jolla?

To join this clinical trial in La Jolla, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this La Jolla clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Colorectal Cancer Metastatic Clinical Trial in La Jolla, CA

About This Colorectal Cancer Metastatic Study in La Jolla

The goal of this clinical trial is to learn whether the combination of balstilimab, botensilimab, and agenT-797 is safe and effective in treating adults with previously treated metastatic colorectal cancer that is microsatellite stable (pMMR) and has spread to the liver. The main questions it aims to answer are: * What proportion of participants experience tumor shrinkage (objective response rate) based on imaging assessments? * What side effects occur with this combination treatment, including immune-related and cytokine-related reactions? All participants in this study will receive the combination treatment. There is no comparison group. Participants will: * Receive balstilimab, botensilimab, and agenT-797 in repeating 42-day treatment cycles * Undergo imaging scans (such as CT or MRI) to assess tumor response * Have blood samples collected to monitor safety and evaluate biomarkers * Provide tumor tissue samples for research * Be monitored for side effects throughout the study * Participate in follow-up visits to assess survival after treatment completion

Sponsor: Darren Sigal, MD

Who Can Participate

Inclusion Criteria

Adults ≥18 years of age with histologically confirmed metastatic colorectal cancer with liver metastases, including evidence of active liver disease if previously treated locally

At least one measurable lesion per RECIST v1.1, with ≥1 target lesion in the liver

Tumor confirmed as microsatellite stable (MSS)/proficient mismatch repair (pMMR) per a FDA-approved assay (Caris MI Cancer Seek®, FoundationOne® CDx, or Tempus xT CDx).

Received ≥1 prior line of systemic therapy including fluorouracil, oxaliplatin, and irinotecan (not necessarily in combination), and prior EGFR inhibitor or bevacizumab if eligible, unless contraindicated

ECOG performance status 0-1 and life expectancy ≥12 weeks

Adequate organ and marrow function:

ANC ≥1.5 × 10⁹/L

Platelets ≥100 × 10⁹/L

Hemoglobin ≥ 9 g/dL

AST/ALT ≤2.5 × ULN

Total bilirubin ≤1.5 × ULN

Creatinine clearance ≥ 40 mL/min, as measured or calculated per local institutional standards.

Albumin ≥3 g/dL

PT/PTT ≤1.5 × ULN

Willing and able to provide written informed consent

Negative pregnancy test for women of childbearing potential

Agreement to use effective contraception during study participation

Exclusion Criteria

Tumor is dMMR/MSI-high

Prior treatment with PD-1, PD-L1, CTLA-4 inhibitors, or other immunotherapy agents

Evidence of bowel obstruction, impending obstruction, or recent obstruction (within 3 months)

Refractory ascites requiring frequent paracentesis or recent escalation of diuretics

Clinically significant cardiovascular disease (e.g., recent myocardial infarction or stroke, unstable angina, NYHA class ≥III heart failure, uncontrolled arrhythmias) or QTc \>480 ms

Active or untreated brain metastases or leptomeningeal disease

Concurrent malignancy requiring treatment or active within 2 years (with protocol-specified exceptions)

Receipt of prior anti-cancer therapy within protocol-defined washout periods, including:

Cytotoxic, targeted therapy or other investigational therapy within 3 weeks.

Monoclonal antibodies, antibody-drug conjugates, radioimmunoconjugates, or similar therapy, within 4 weeks, or 5 half-lives, whichever is shorter.

Small molecules/tyrosine kinase inhibitors within 2 weeks or less than 5 circulating half-lives of investigational drug.

Known hypersensitivity to study drugs or excipients

History of or active interstitial lung disease or pneumonitis requiring systemic steroids

Prior allogeneic transplant (organ, stem cell, or bone marrow)

Active or recent autoimmune disease requiring systemic treatment

Requirement for systemic corticosteroids (\>10 mg prednisone equivalent) or other immunosuppressive therapy within defined windows

Active infection, including HIV, HTLV, HBV, HCV, or other infections requiring systemic therapy

Recent SARS-CoV-2 infection within protocol-defined timeframe

Uncontrolled hypertension, significant proteinuria (UPCR ≥1 g/g), or other clinically significant uncontrolled medical conditions

Non-healing wounds, active bleeding, or uncontrolled thyroid dysfunction

Psychiatric or substance use disorders that may interfere with study participation

Receipt of live or attenuated vaccines within 30 days prior to treatment and while participating in the study

Pregnant or breastfeeding women, or those planning pregnancy during the study

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in La Jolla?

Yes, this clinical trial (NCT07550088) has an active research site in La Jolla, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Colorectal Cancer Metastatic Treatment Options in La Jolla, CA

If you're searching for colorectal cancer metastatic treatment options in La Jolla, CA, this clinical trial (NCT07550088) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our La Jolla research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced colorectal cancer metastatic specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all colorectal cancer metastatic clinical trials near you to find additional studies recruiting in your area.

Colorectal Cancer Metastatic Clinical Trial in La Jolla, CA

Expert Care in La Jolla

IRB Approved

No-Cost Care

Apply for This La Jolla Location

Why Participate?

Simple Process